Abeona Therapeutics (NASDAQ:ABEO) Now Covered by Analysts at Oppenheimer

Oppenheimer started coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report published on Wednesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $16.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on ABEO. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, February 19th. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $5.26 on Wednesday. The stock has a market capitalization of $228.66 million, a P/E ratio of -1.96 and a beta of 1.79. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $9.01. The company has a 50 day moving average of $5.58 and a 200-day moving average of $5.85. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds have recently added to or reduced their stakes in ABEO. Adage Capital Partners GP L.L.C. lifted its holdings in Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after purchasing an additional 652,366 shares during the last quarter. Western Standard LLC lifted its holdings in Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after purchasing an additional 386,321 shares during the last quarter. Jane Street Group LLC lifted its holdings in Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 118,262 shares during the last quarter. 683 Capital Management LLC lifted its holdings in Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after purchasing an additional 116,845 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Abeona Therapeutics during the 4th quarter valued at $520,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.